Roche to Invest $50B in US Over Next 5 Years (Connecting the Dots: Hoffmann-La Roche, The Raben Group & Soros Funding, All Networking)
Newsmax.com
Tuesday,
22 April 2025 06:17 AM EDT
https://www.newsmax.com/finance/streettalk/roche-switzerland-pharmaceuticals/2025/04/22/id/1207808/
Swiss
pharmaceuticals powerhouse Roche announced it plans to invest $50 billion in the
United States over the next five years, creating 12,000 jobs.
The
Basel-based company, whose array of products includes cancer medicines and
multiple sclerosis treatment Ocrevus, said on Monday the investment would go
toward high-tech research and development sites and new manufacturing
facilities in places including California, Indiana, Massachusetts and
Pennsylvania.
The
announcement comes as U.S. President Donald Trump has urged foreign businesses
to invest more in the United States and announced sweeping tariffs earlier this
month on imports as part of hopes to reduce a large U.S. trade deficit when it
comes to sales of goods.
Before
the Trump administration backed off its most stringent tariff plans, products
imported from Switzerland had been set to face tariffs of 31% — more than the
20% tariffs on goods from the European Union. Switzerland is not a member of
the 27-country bloc but is virtually surrounded by four EU countries.
Trump's
sweeping “Liberation Day” tariffs on April 2 set off turmoil in world stock
markets. A week later, Trump spoke by phone with Swiss President Karin
Keller-Sutter in a conversation that her office said focused on tariffs. She
emphasized the “important role of Swiss companies and investments in the United
States.”
Hours
later, the U.S. president announced the U-turn that paused the steep new
tariffs on about 60 countries for 90 days, fanning speculation — which was not
confirmed — in some Swiss media that her chat with Trump might have played a
role in the change of course.
Roche,
in its statement, said that once the new, expanded manufacturing comes on line,
the company “will export more medicines from the U.S. than it imports” — though
it made no mention of tariffs.
"Today’s
announced investments underscore our longstanding commitment to research,
development and manufacturing in the U.S.,” said Roche CEO Thomas Schinecker in
a statement.
The
company — like cross-town competitor Novartis — has deep ties to the U.S.
market and said it currently employs 25,000 people and operates 15 R&D
centers and 13 manufacturing sites in the United States.
The
planned investment will add 1,000 jobs at Roche in the U.S. and “more than
11,000 in support of new U.S. manufacturing capabilities,” it said, which will
increase its footprint in the United States to 24 sites in eight states.
Roche
tallied more than 60 billion Swiss francs (about $74 billion) in worldwide
sales last year, and nearly 25 billion francs of sales in its key
pharmaceuticals division alone came in the United States. Roche’s share price
has fallen by about 18% over the past month, with most of the drop coming after
the U.S. tariff announcement on April 2.
Connecting
the Dots:
Raben Group was
the lobby firm for Hoffmann-La Roche, the Morehouse School of
Medicine and is the NAACP Legal Defense & Educational Fund.
Eric H. Holder Jr. is
a trustee at the Morehouse School of Medicine, was the attorney
general at the U.S. Department of Justice for the Barack
Obama administration, an intern at the NAACP Legal Defense & Educational
Fund and a board member for the American Constitution Society.
Foundation to Promote Open Society was a funder for the NAACP
Legal Defense & Educational Fund and the Center for American
Progress.
George Soros was the chairman for the Foundation to Promote
Open Society, a supporter for the Center for American Progress and
is the founder & chairman for the Open Society Foundations.
Open Society Foundations was a funder for the American
Constitution Society, the Alliance for Justice and the Center
for American Progress.
Robert Raben was
a director at the American Constitution Society, an assistant
attorney general for the U.S. Department of Justice, is a director
at the Alliance for Justice and the president for the Raben
Group.
Raben Group was
the lobby firm for Hoffmann-La Roche.
Melody C. Barnes was
a principal for the Raben Group, the domestic policy council,
director for the Barack Obama administration, the EVP for the Center
for American Progress and is Barack Obama’s golf partner.
Resources:
Past Research
GE,
Walmart, AT&T, Google Among Donors (Past Research
on the Center for American Progress)
Saturday,
December 14, 2013
https://thesteadydrip.blogspot.com/2013/12/ge-walmart-at-google-among-center-for.html
WHO
list reveals flu advisors with financial ties to pharma, vaccine manufacturers (Past Research on the Hoffmann-La Roche)
Saturday,
October 19, 2013
https://thesteadydrip.blogspot.com/2013/10/who-list-reveals-flu-advisors-with.html
No comments:
Post a Comment